SCHEMBL4419607

SCHEMBL4419607

COc1cc(OS(=O)(=O)c2cccc(Cl)c2)ccc1-c1ccc2c(c1COc1cc(F)ccc1C)C(C)=CC(C)(C)N2

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IL6 P05231 8/20 0.45
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PGR P06401 7/20 0.39
NR3C1 P04150 6/20 0.39
ESR1 P03372 1/20 0.37
AR P10275 1/20 0.37
ESR2 Q92731 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
PTBP1 P26599 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423701 0.93 IL6 (0.46) IL6MAPTALDH1A1HPGDHTT
SCHEMBL4420373 0.92 MAPT (0.47) IL6MAPTALDH1A1HPGDHTT
SCHEMBL4415311 0.92 IL6 (0.47) IL6MAPTALDH1A1HPGDHTT
SCHEMBL4420398 0.90 MAPT (0.49) IL6MAPTALDH1A1HPGDHTT
SCHEMBL4415335 0.88 IL6 (0.45) IL6MAPTALDH1A1HPGDHTT
SCHEMBL14847496 0.87 IL6 (0.47) IL6MAPTALDH1A1PGRNR3C1
SCHEMBL4418092 0.87 IL6 (0.47) IL6MAPTALDH1A1HPGDHTT
SCHEMBL1316189 0.86 IL6 (0.50) IL6MAPTALDH1A1HPGDHTT
SCHEMBL4426059 0.86 IL6 (0.46) IL6MAPTALDH1A1HPGDHTT
SCHEMBL2392515 0.86 IL6 (0.47) IL6PGRNR3C1ESR1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440660-B2 Method for treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-05-14 US disclosed
EP-2085387-B1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO LTD (JP) 2013-04-10 EP disclosed
EP-2085387-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed
US-7507824-B2 Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors N.V. ORGANON (NL) 2009-03-24 US disclosed
US-20040029904-A1 Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors MERCK SHARP & DOHME B.V. (NL) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029904-A1 Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors SLC6A7, SLC1A2, SLC6A1 IL6 2459/4885MAPT 1343/4885ALDH1A1 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.